Drugs / YL-13027
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06199466 | Jan 2024 → Sep 2025 | malignant pancreatic neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT05228600 | May → Dec 2022 | cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03869632 | Mar 2019 → Apr 2021 | cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06662669 | Nov 2024 → Sep 2027 expected | malignant pancreatic neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05457517 | Sep 2022 → Jun 2024 | cancer | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL-13027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06662669 ↗ |
| Action | Inhibit | “inhibits protein serine/threonine kinase of activin receptor-like kinase 5 (ALK5)” NCT03869632 ↗ |
| Modality | Small molecule | “YL-13027 is an orally bioavailable small molecule” NCT03869632 ↗ |
| Route | Oral | “YL-13027 is given orally daily.” NCT03869632 ↗ |
| Target | TGFBR1 | “YL-13027 is a novel small molecule TGF-βR1 inhibitor.” NCT05228600 ↗ |